REMAP-CAP • Coronavirus
REMAP-CAP: Mixed Results for Antiplatelets in Critical COVID-19 | tctmd.com
Full article: Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19
Media — REMAP-CAP Trial
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia: REMAP-CAP | DREEAM
remap-cap (@remap_cap) / X
Homepage - REMAPCAP
Media — REMAP-CAP Trial
May 15, 2020: Optimized Learning While Doing: The REMAP-CAP Adaptive Platform Trial (Derek Angus, MD, MPH) - Rethinking Clinical Trials
Media — REMAP-CAP Trial
How will 'mega-trials' identify the most effective treatments for COVID-19, and when will they report? - Coronavirus: the science explained - UKRI
Homepage - REMAPCAP
Understanding Adaptive Platform Trials & REMAP-CAP - SingHealth
Site education — REMAP-CAP Trial
Statement from the REMAP-CAP trial on blood thinners in COVID-19 patients | Imperial News | Imperial College London
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial | SpringerLink
REMAP-CAP awarded Critical Care Team of the Year at The BMJ Awards 2021 | Imperial News | Imperial College London
NHMRC Clinical Trial Centre | Improving Health Outcomes
